Leber’S Hereditary Optic Neuropathy

A significant improvement of visual acuity was reported in eyes treated with a unilateral intravitreal injection of lenadogene nolparvovec for Leber hereditary optic neuropathy, researchers reported at the 2022 American Academy of Neurology annual meeting.

Patients with Leber hereditary optic neuropathy treated with Lumevoq experienced sustained efficacy and safety after 2 years as part of the phase 3 REFLECT clinical trial, according to a press release from GenSight Biologics.

An analysis from clinical trials and natural history studies showed a statistically significant difference in visual outcomes between Lumevoq-treated patients and untreated patients, according to a press release from GenSight Biologics.

A natural history study shows patients who have Leber’s hereditary optic neuropathy with the ND4 mutation have a dramatic and irreversible decline in visual acuity, a press release from GenSight Biologics said.